Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT trial of 3-week versus 6-week prednisolone for mild immune checkpoint inhibitor-related pneumonitis
jRCTs051220082Completed
- Start
- Sep 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of prednisolone in Checkpoint inhibitor pneumonitis (CIP) and Drug-Induced Pneumonia (2 arms). Primary endpoint: Percentage of patients showing improvement. Started Sep 2022; status: completed.
02
Drugs
prednisolone
03
Conditions
Checkpoint inhibitor pneumonitis (CIP)Drug-Induced Pneumonia
Beyond the preview
Go deeper on jRCTs051220082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051220082.